Clinical, Genomic, and Pathology Real-World Data (RWD) Market Landscape Assessment

Secondary Research

• Compiled information on the offerings of the top 10 RWD players; gathered competitive landscape data regarding collaborations between biopharma and RWD providers; analyzed FDA guidelines regarding the use of RWD in regulatory submissions

Primary Research

• Conducted 20 in-depth interviews with senior-level stakeholders from small, medium, and large U.S. oncology-focused biopharma, capturing perspectives on RWD utility across the drug development pipeline (i.e., Discovery, Translational, Clinical Development, Med Affairs, RWE / HEOR)

Quantitative Analysis

• Projected competitor market share and overall RWD market penetration based on interviewee examples of RWD acquisitions; calculated the average per project / per license spend and annual RWD budgets by biopharma size; and estimated growth trajectories of RWD split by cancer type and data acquisition / pricing model

Key takeaways from DeciBio's work included:

• A “fact base” regarding the primary use cases, users, and unmet needs of clinical, genomic, and pathology RWD
• “Voice-of-customer” feedback in an organic, blinded fashion, used to advise client on key offering additions and adjustments
• A semi-quantitative assessment the RWD market size, penetration, and growth rate with splits by data acquisition and pricing model